山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告

Core Viewpoint - The company, Shandong Oriental Ocean Technology Co., Ltd., has received approval for its Interleukin-6 (IL-6) testing kit, which may have uncertain impacts on its future performance [3][4]. Group 1: Product Information - The IL-6 testing kit (fluorescent immunochromatography method) has been registered and approved by the Shandong Provincial Drug Administration, obtaining a medical device registration certificate for in vitro diagnostic reagents [3]. Group 2: Impact on Company - The approval of the IL-6 testing kit enriches the product line of the company's subsidiary, Aiveco Biotechnology Co., Ltd., in the clinical testing field [3]. - However, the impact of Aiveco on the company's performance this year is minimal, and the production and subsequent performance of the new product remain uncertain [3][4]. Group 3: Market Considerations - The actual sales of the newly approved product will depend on multiple factors, including market expansion efforts and actual market demand, making it currently impossible to predict its specific impact on future performance [3][4].